PMID- 9204961
OWN - NLM
STAT- MEDLINE
DCOM- 19970717
LR  - 20220331
IS  - 0022-202X (Print)
IS  - 0022-202X (Linking)
VI  - 109
IP  - 1
DP  - 1997 Jul
TI  - Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin.
PG  - 91-5
AB  - Retinoids exert their biologic effects through two families of nuclear receptors, 
      retinoic acid receptors (RARs) and retinoid X receptors (RXRs), which belong to 
      the superfamily of steroid/thyroid hormone nuclear receptors. By using a 
      subtraction hybridization approach, we have identified a cDNA sequence TIG2 
      (Tazarotene-induced gene 2), whose expression is up-regulated by the treatment of 
      skin raft cultures by an RAR beta/gamma-selective anti-psoriatic synthetic 
      retinoid tazarotene [AGN 190168/ethyl 
      6-[2-(4,4-dimethylthiochroman-6-yl)-ethynyl] nicotinate]. The retinoid-mediated 
      up-regulation in the expression of TIG2 was confirmed by Northern blot analysis. 
      Upon sequencing, TIG2 was found to be a cDNA whose complete sequence was not in 
      the GenBank and EMBL data bases. The TIG2 cDNA is 830 bp long and encodes a 
      putative protein product of 164 amino acids. TIG2 is neither expressed nor 
      induced by tazarotene in primary keratinocyte and fibroblast cultures. Thus, TIG2 
      is expressed and induced by tazarotene only when keratinocytes and fibroblasts 
      form a tissue-like 3-dimensional structure. We further demonstrate that 
      RAR-specific retinoids increase TIG2 mRNA levels. In contrast, neither 
      RXR-specific retinoids nor 1,25-dihydroxyvitamin D3 increased TIG2 levels. 
      Finally, we demonstrate that TIG2 is expressed at high levels in nonlesional 
      psoriatic skin but at lower levels in the psoriatic lesion and that its 
      expression is up-regulated in psoriatic lesions after topical application of 
      tazarotene.
FAU - Nagpal, S
AU  - Nagpal S
AD  - Department of Biology, Allergan, Inc., Irvine, California 92713, U.S.A.
FAU - Patel, S
AU  - Patel S
FAU - Jacobe, H
AU  - Jacobe H
FAU - DiSepio, D
AU  - DiSepio D
FAU - Ghosn, C
AU  - Ghosn C
FAU - Malhotra, M
AU  - Malhotra M
FAU - Teng, M
AU  - Teng M
FAU - Duvic, M
AU  - Duvic M
FAU - Chandraratna, R A
AU  - Chandraratna RA
LA  - eng
GR  - AR39915/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Invest Dermatol
JT  - The Journal of investigative dermatology
JID - 0426720
RN  - 0 (DNA, Complementary)
RN  - 0 (Nicotinic Acids)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (Retinoid X Receptors)
RN  - 0 (Transcription Factors)
RN  - 81BDR9Y8PS (tazarotene)
RN  - FXC9231JVH (Calcitriol)
SB  - IM
MH  - Administration, Topical
MH  - Amino Acid Sequence
MH  - Base Sequence
MH  - Calcitriol/pharmacology
MH  - Cells, Cultured
MH  - Chromosome Mapping
MH  - Chromosomes, Human, Pair 17/genetics
MH  - DNA, Complementary/metabolism
MH  - Gene Expression/drug effects
MH  - Humans
MH  - Molecular Sequence Data
MH  - Nicotinic Acids/administration & dosage/*genetics
MH  - Psoriasis/genetics
MH  - RNA, Messenger/metabolism
MH  - Receptors, Retinoic Acid/genetics/physiology
MH  - Retinoid X Receptors
MH  - Sequence Homology, Nucleic Acid
MH  - Skin/cytology
MH  - *Skin Physiological Phenomena
MH  - Transcription Factors/genetics/physiology
MH  - Up-Regulation
EDAT- 1997/07/01 00:00
MHDA- 1997/07/01 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/07/01 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
AID - S0022-202X(15)42952-5 [pii]
AID - 10.1111/1523-1747.ep12276660 [doi]
PST - ppublish
SO  - J Invest Dermatol. 1997 Jul;109(1):91-5. doi: 10.1111/1523-1747.ep12276660.